CVS tilbake med å dekke Zepbound
https://www.washingtonpost.com/health/2026/05/28/ozempic-may-be-reshaping-brain-scientists-say/
Mer kreft data:
OS at 24 months was higher among GLP1 users versus nonusers for both breast cancer (97.9% [95% CI 93.7–99.3] vs 92.6% [92.4–92.8]) and prostate cancer (97.9% [93.7–99.3] vs 92.6% [92.4–92.8]). After adjustment for age, BMI, stage, and cancer type, GLP1 use was significantly associated with improved OS (HR 0.58, 95% CI 0.40–0.84; p = 0.0036).
Har ikke GLP1 blitt testet på kreft før? I ordentlig fase 2/3 studie.
Overrasker meg ikke om det har stor effekt, når man vet hvor enorme positive effekter det har på kroppen og gå ned i vekt
Nei, har vel bare blitt testet som tillegsinfo at det ikke øker kreftfaren etter hva jeg kan se. Er vel det litt av disse resultatene nå etterspør, at det trengs direkte større randomiserte studier som kan bekrefte signalene som er gitt her
“…supporting the need for future studies using robust causal inference approaches.”
“These findings warrant validation in prospective randomized controlled trials and mechanistic investigation of potential antineoplastic pathways driven by GLP-1RAs.”
Begynner å komme litt data i dag:
Resten kan sjekkes ut på ADA 2026 Scientific Sessions Planner
All data fra presentasjoner iløpet av neste uke
Lurer på om ikke Altimmune sin lille fase II med 100 pasienter i AUD (Alcohol Use Disorder) burde lese av i løpet av sommeren. Blir spennede å se om man kan se effekt der.
Noen som kjenner til årsaken bak dagens fall i Novo?
Markedet frykter NovoNordisk må betale for dyrt for en avtale med Nanexa 
Er generelt hele sektoren som faller litt tilbake. Lilly -6%, Viking -11%, Structure -11%, Gubra -6% og Zealand -8% de siste dagene.
EDIT:
Mange av disse vil nok forhåpentlig hente seg inn når fokuset flyttes mot ADA til helgen
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
2026-06-03 08:00:52
- Novo Nordisk launches Wegovy® pill in the United Arab Emirates today
- Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term
- Wegovy® pill, providing a mean weight loss of 17%, is the only weight-loss pill approved to reduce the risk of major adverse cardiovascular events (MACE), including heart attack and stroke, in adults with established cardiovascular disease and obesity or overweight
Bagsværd, Denmark, 3 June 2026 - Novo Nordisk today announced the launch of Wegovy® pill (semaglutide tablets) in the United Arab Emirates (UAE), the first country outside the United States to make the Wegovy® pill available to people living with obesity. The launch marks an important step in Novo Nordisk’s ambition to expand access to innovative obesity treatments and broaden treatment options for people living with obesity around the world.
“I am thrilled that Wegovy® pill is now available in the UAE,” said Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk. “This launch represents an important milestone in our ambition to expand access to innovative obesity care globally. As we look to future launches, our approach will be guided by local patient demand, the readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure that can support long-term obesity care. The UAE has demonstrated strong momentum across all of these areas, and we look forward to bringing Wegovy® pill to additional select countries in the coming months.”
The Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS 4 trial programme.
In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated ~17% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities. The weight loss achieved with the Wegovy® pill is similar to that of injectable Wegovy® 2.4 mg. Furthermore, 1 in 3 people experienced 20% or greater weight loss in the OASIS 4 trial. The established safety and tolerability profile of semaglutide was reaffirmed with Wegovy® pill in the OASIS 4 trial, which was comparable to previous trials with semaglutide for weight management.
Wegovy® pill is also the only weight-loss pill approved by both the FDA and the Emirates Drug Establishment (EDE) to reduce the risk of major adverse cardiovascular events (MACE), including heart attack and stroke, in adults with established cardiovascular disease and obesity or overweight.
Worldwide, 1 billion people live with obesity, and in the UAE, 28% of adults are living with obesity, with almost 7.5 million people projected to be living with obesity or overweight by 2035.
Novo Nordisk has previously announced that we will launch Wegovy® pill in select markets in the second half of 2026.
Månedschartet i Novo er ganske compelling. Se momentumindikatorene der, sammen med en mulig vellykket backtest av 50 dagers snitt
Det som er negativt er at den lange tunge trenden er intakt
Jepp, lower risk movet er å vente på at man får et definitivt brudd oppover, og helst litt momentum på bevegelsen, alt før det er og blir knivfanging i det lange bildet 
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to placebo, with up to 89.1% achieving A1C below 7%1 Additionally, participants treated with zenagamtide showed body weight loss up to 14.6% at week 36 with the highest dose investigated, 40 mg1 Zenagamtide will advance into phase 3 clinical trials in adults with type 2 diabetes based on these resultsPLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 5, 2026 /PRNewswire/ – Novo Nordisk today announced new clinical data from the positive phase 2 trial of investigational zenagamtide, also known as amycretin. Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.1 Presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans, LA, results from the phase 2 dose finding study included the evaluation of six subcutaneous doses of zenagamtide (ranging from 0.4 mg to 40 mg) versus matched placebo in 262 adults with type 2 diabetes inadequately controlled (A1C 7.0–10.0%) on metformin, with or without an SGLT2 inhibitor. The study met its primary endpoint of change in A1C across all doses and also key supportive secondary endpoint of change in body weight (with doses 1.5 mg and greater) with zenagamtide versus placebo after 36 weeks.1
“Zenagamtide is the first investigational treatment for type 2 diabetes to combine GLP-1 and amylin receptor agonist mechanisms of action in a single molecule. These phase 2 results build on the growing body of evidence which demonstrates the potential of zenagamtide to meaningfully impact blood glucose control in patients with type 2 diabetes and also body weight,” said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. “These results underscore our scientific leadership and position us to continue advancing innovative treatment options that could expand the therapeutic landscape and provide patients and healthcare professionals with greater choice in managing type 2 diabetes.”
The phase 2 study showed a dose-dependent and statistically significant change in A1C from baseline to week 36 with all doses vs placebo. From a baseline of 7.8%, the estimated mean change in A1C at week 36 was up to ‒1.71% with zenagamtide 40 mg (estimated treatment difference [ETD] vs placebo: ‒1.56% [95% confidence interval (CI): ‒2.05, ‒1.07]; p<0.0001).1 Up to 89.1% of participants on zenagamtide achieved A1C levels below 7%, and up to 76.2% achieved levels at or below 6.5%.1 Notably, the proportion of time spent within target range of 70–180 mg/dL (3.9–10.0 mmol/L) was above the internationally recommended target of >70% across all zenagamtide doses investigated (up to 91.5% with zenagamtide 40 mg).1 These results suggest strong glycemic efficacy, considering that the higher zenagamtide dose treatment groups were only exposed to the maintenance dose for a short period of time (ie 20 mg for 8 weeks and 40 mg for 4 weeks).1
As a key supportive secondary endpoint, trial participants taking zenagamtide also saw a mean body weight reduction of up to 14.6% (baseline body weight ~219 lbs) with the 40 mg dose compared with 2.1% with placebo.1 No apparent weight loss plateau was seen at week 36 with the higher doses of zenagamtide.1
Table. Endpoints: once-weekly subcutaneous zenagamtide vs placebo
Once-weekly subcutaneous zenagamtide
Participant (N=262) baseline characteristics: Male 66%; mean age 57.1 yrs; A1C 7.8%; body weight 99.2 kg (218.7 lbs); 40% on SGLT2i.
All patients on a stable dose of metformin with or without SGLT2 inhibitor.
Each endpoint was analyzed using an ANCOVA model. The analyses were based on data from the on-treatment without rescue medication observation period.
Using the dose–response model for analysis, the estimated mean change in A1C from baseline to week 36 was up to –1.8% (ETD vs placebo [95% CI]: –1.58 [–2.08, –1.08]; p<0·0001); the estimated mean change in body weight was up to –14.5% (ETD vs placebo [95% CI]: –11.81 [–15.37, –8.25]; p<0.0001), with zenagamtide 40 mg.
This trial used a fixed-dose-escalation trial design; if the planned treatment dose was not tolerated, treatment was permanently discontinued.
In the trial, the most common adverse events were gastrointestinal, and the majority were mild to moderate in severity. The safety and tolerability profile in this phase 2b trial was consistent with other incretin and amylin-based therapies. These results support further investigation of zenagamtide in phase 3 trials.1
Based on the results, Novo Nordisk is planning to initiate a phase 3 development program with zenagamtide for adults with type 2 diabetes in H2 2026.
Er vel denne som ikke ser helt bra ut:
Flere postere vil dukke opp her:
https://sciencehub.novonordisk.com/congresses/ada2026.html
Og bilder av noen slides fra x:
Voldsomt med bivirkninger på zenagamtide. 20 og 40 mg blir nok for heftig, diabetes er en folkesykdom, kan ikke ha så mye bivirkninger som det der.
UBT251 ser dog mye mer lovende ut! Den kan absolutt konkurrere med Retatrutide for fedme👍
Spørsmålet her er vel om de har økt for fort. Og om mange flere kunne blitt holdt i trial om man hadde vært mer fleks. Men Novo gjorde jo det med CagriSema, og resultatet ble jo at selskapet selv + investorene egentlig ikke helt vet hvor bra / dårlig produktet egentlig er. Når det er sagt så begynner vi å se at GLP-1 + amylinagonist som targeter calcitoninreseptor ikke akkurat gir utmerket toleranse. Kan se ut som LLY traff veldig bra med 1:1 GLP-1 og GIP i tirzepatide. GIP-agonisten ser rett og slett ut til å motvirke en del AE’s.
Vi får se om Novo finner ut at de vil lage seg en “basisdrug” med ca. samme egenskaper. Kan være de henter sin egen double agonist ned fra hylla. Eller kanskje kjøper en. Har tidligere skrevet at Novo neppe ville være interessert i VKTX pga egen pipe. Men slik pipen til Novo utvikler seg nå, så kan en godt balansert GLP1/GIP-agonist i bakhånd være en smart move.
